Approval marks CELYSTRA Pharma’s second product approved by Health Canada in nine months and brings a new treatment option for Canadians living with hereditary angioedema.
Illuminating life at the cellular level
Latest News
-
Revitalizing Our Pharmaceutical Industry
In La Presse, Paul Lévesque, President and CEO of Celystra Pharma, makes the case for revitalizing Quebec’s pharmaceutical industry in the face of the Trump administration’s “most favoured nation” rule, which threatens Canadians’ access to new medicines. He calls on the government to bring health and economic development together to make Quebec a global leader in life sciences.
-
CELYSTRA Pharma at the 25th Annual Market Access Summit in Toronto
Paul Lévesque, President, CEO and Co-Founder of CELYSTRA Pharma, spoke at the 25th Annual Market Access Summit. He discussed launch strategy in Canada amid long approval timelines and global uncertainty.